We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

84 hedge funds and large institutions have $349M invested in Iovance Biotherapeutics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,745% more call options, than puts

Call options by funds: $3.43M | Put options by funds: $186K

76.4% more ownership

Funds ownership: 0% → 76.4% (+76%)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

4% more funds holding

Funds holding: 81 → 84 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less capital invested

Capital invested by funds: $361M → $349M (-$11.8M)

13% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 30

Holders
84
Holders Change
+3
Holders Change %
+3.7%
% of All Funds
2.09%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
13
Increased
26
Reduced
30
Closed
9
Calls
$3.43M
Puts
$186K
Net Calls
+$3.25M
Net Calls Change
+$2.19M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$6.92M
2
PA
Perceptive Advisors
New York
+$5.06M
3
Millennium Management
Millennium Management
New York
+$2.65M
4
GPP
Great Point Partners
Connecticut
+$1.07M
5
NFA
Nationwide Fund Advisors
Ohio
+$681K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.41M
2
QF
QVT Financial
New York
-$4.61M
3
GTC
Ghost Tree Capital
New York
-$4.13M
4
Northern Trust
Northern Trust
Illinois
-$2.56M
5
ACA
Avoro Capital Advisors
New York
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$1.32M +$226K +35,599 +25%
GPP
27
Great Point Partners
Connecticut
$1.24M +$1.07M +169,014 New
TA
28
Teachers Advisors
New York
$1.08M +$379K +59,600 +69%
NFA
29
Nationwide Fund Advisors
Ohio
$1.02M +$681K +107,190 +334%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$688K -$111K -17,500 -16%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$677K +$585K +92,099 New
Swiss National Bank
32
Swiss National Bank
Switzerland
$655K +$92.2K +14,500 +19%
Wells Fargo
33
Wells Fargo
California
$528K +$138K +21,654 +43%
SM
34
Sabby Management
Florida
$524K +$70.5K +11,095 +18%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$468K +$32K +5,030 +9%
Deutsche Bank
36
Deutsche Bank
Germany
$456K +$249K +39,201 +171%
AllianceBernstein
37
AllianceBernstein
Tennessee
$453K +$140K +22,000 +56%
Russell Investments Group
38
Russell Investments Group
United Kingdom
$380K – – –
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$375K -$6 -1 -0%
Morgan Stanley
40
Morgan Stanley
New York
$373K -$210K -32,986 -39%
VEA
41
Virtus ETF Advisers
New York
$364K +$64.3K +10,116 +26%
CM
42
Crestline Management
Texas
$318K +$275K +43,254 New
CIBC Private Wealth Group
43
CIBC Private Wealth Group
Georgia
$316K – – –
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$308K -$19.3K -3,031 -7%
PCM
45
Prelude Capital Management
New York
$291K -$1.91K -300 -0.8%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$287K +$248K +39,000 New
ProShare Advisors
47
ProShare Advisors
Maryland
$270K -$19.2K -3,023 -8%
SSA
48
Schonfeld Strategic Advisors
New York
$250K +$216K +34,024 New
AIG
49
American International Group
New York
$241K -$8.93K -1,405 -4%
LCM
50
Landscape Capital Management
New Jersey
$236K – – –
1
2
3 4

IOVA Hedge Fund Activity: Q2 2017 in Review

84 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2017, worth a combined $349M — down 3.3% from $361M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IOVA positions and 9 closed out — a net gain of 4 holders — while 26 added to existing stakes and 30 trimmed.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $6.92M. The largest seller was Fidelity Investments, cutting an estimated $6.41M.

  • 84 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2017, up from 81 in Q1 2017.
  • Funds reported $349M of Iovance Biotherapeutics stock for Q2 2017, down 3.3% quarter-over-quarter.
  • 13 funds opened new Iovance Biotherapeutics positions in Q2 2017 and 9 closed out, a net change of +4 holders.
  • The largest Iovance Biotherapeutics buyer in Q2 2017 was JP Morgan Chase, an estimated $6.92M added.
  • The largest Iovance Biotherapeutics seller in Q2 2017 was Fidelity Investments, an estimated $6.41M sold.

Based on aggregated 13F filings for Q2 2017.